IRF2BPL

Across TCGA pan-cancer cohorts, IRF2BPL Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IRF2BPL data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher IRF2BPL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IRF2BPL expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, UCEC, and LUAD are the cancer types where IRF2BPL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.228	0.708	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.831	.035	4	view →
LUAD	DFS	Median	All	0.502	0.769	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

IRF2BPL–ESCA (OS)

Open the ESCA breakdown →